Miroculus Status
The company raised $17.21 million of Series B venture funding from undisclosed investors on August 21, 2018, putting the company's pre-money valuation at $35 million.
Provider of hands-off sample-to-answer solutions designed for molecular testing. The company's solution leverages a proprietary digital microfluidics technology to automate manually intensive experimental workflows on a low-cost cartridge, enabling users to have access to accurate, affordable and minimally invasive molecular testing
Year Founded
2013
Employees
25
General Information
-
Website
-
Business Status
Generating Revenue
-
Ownership Status
Privately Held (backing)
-
Financing Status
Venture Capital-Backed
Miroculus News and Updates
Interpace Biosciences Posts 6 Percent Revenue Increase in Q1
GenomeWeb | May 17, 2022
Pacific Biosciences Partners with Japan's iLAC, RBI on Automated Sequencing Workflows
GenomeWeb | May 9, 2022
Miroculus Appoints Mark Lewis as Executive Chairman
Business Wire | April 19, 2022
Miroculus's Feed
Miroculus's Verticals
Miroculus Primary Industry Sector / Group / Code
Miroculus's Trends
Miroculus Metrics
Growth Rate
SimilarWeb Unique Visitors
Twitter Followers
Headquarters
-
HQ Address Line 1458 Brannan Street
-
HQ Address Line 2Office 118
-
HQ CitySan Francisco
-
HQ State/ProvinceCalifornia
-
HQ Post Code94107
-
HQ CountryUnited States
Add a review